NRG2 (Neuregulin-2) is a member of the neuregulin family of growth factors that serve as ligands for ErbB receptor tyrosine kinases. Like its better-characterized relative NRG1, NRG2 plays critical roles in nervous system development, glial cell function, synaptic plasticity, and neuronal survival. While NRG2 has been less extensively studied than NRG1, emerging evidence suggests it has distinct physiological functions and may be relevant to neurodegenerative and psychiatric disorders including Alzheimer's disease (AD), Parkinson's disease (PD), schizophrenia, and autism spectrum disorder (ASD). The protein is expressed in specific neuronal and glial populations and signals through ErbB3 and ErbB4 receptors to regulate diverse cellular processes essential for neural circuit formation and maintenance.
The NRG2 gene (located on chromosome 5q31.2 in humans) encodes a type I transmembrane protein of 642 amino acids with a molecular weight of approximately 70 kDa (full-length) that is proteolytically processed to generate an ~40 kDa soluble growth factor domain. NRG2 belongs to the neuregulin family, which includes NRG1, NRG2, NRG3, and NRG4 in humans. Unlike NRG1, which has multiple isoforms generated by alternative splicing, NRG2 has a simpler isoform structure with fewer splice variants.
NRG2 possesses several distinctive structural domains:
The EGF-like domain is the critical functional region, binding to ErbB receptors with specificity different from NRG1. Proteolytic cleavage by ADAM proteases releases the soluble growth factor domain, which can then activate neighboring cells in a paracrine or autocrine manner. [1]
NRG2 exhibits a more restricted expression pattern than NRG1:
In the brain, NRG2 is predominantly expressed in:
This distribution suggests distinct functions from NRG1, which is more broadly expressed. [2]
NRG2 binds primarily to ErbB3 and ErbB4 receptors (with lower affinity for ErbB2 as a co-receptor):
Receptor binding profile:
Upon ligand binding, ErbB receptors dimerize and autophosphorylate, activating downstream signaling pathways:
This signaling is essential for neural development and plasticity. [3]
NRG2 participates in multiple developmental processes:
Schann cell development:
Oligodendrocyte function:
Neuronal development:
This function explains why NRG2 is being explored for demyelinating diseases. [4][5]
NRG2 has emerged as an important regulator of synaptic function:
Excitatory synapses:
Inhibitory synapses:
Circuit-level effects:
These synaptic functions link NRG2 to psychiatric and neurodegenerative disorders. [6][7]
Multiple lines of evidence link NRG2 to schizophrenia:
Genetic association: While NRG1 has stronger genetic evidence, NRG2 polymorphisms have been associated with schizophrenia in some populations, though results have been inconsistent.
Pathophysiology:
Mechanism: NRG2-ErbB4 signaling regulates GABAergic interneuron function, and dysfunction in this pathway may contribute to the characteristic circuitry abnormalities in schizophrenia. [8][9]
Emerging evidence implicates NRG2 in AD pathogenesis:
Expression changes:
Therapeutic potential:
Mechanism:
This makes NRG2 a potential therapeutic target for AD. [10]
In PD, NRG2 may play protective roles:
Neuroprotection:
Therapeutic potential:
The growth factor properties make NRG2 attractive for PD neuroprotection strategies. [11]
NRG2 signaling is relevant to MS pathophysiology:
Remyelination:
Therapeutic approach:
This positions NRG2 as a potential remyelination therapy. [5:1][12]
NRG2 variants have been associated with ASD:
Genetic evidence:
Mechanism:
This suggests NRG2 may contribute to neurodevelopmental disorders. [13]
While NRG1 is the most well-studied neuregulin:
See: NRG1
NRG2 is part of the broader neuregulin signaling network:
See: Neuregulin signaling mechanism
NRG2 as a therapeutic agent:
ErbB receptor agonists:
Viral vector delivery:
NRG2 may synergize with:
'Falls DL, et al'. Neuregulins: Function, structure, and signaling. Dev Neurobiol. 2003. ↩︎
'Irie N, et al'. Spatial expression of neuregulin-2 in the brain. Neurosci Res. 2005. ↩︎
'Britt DE, et al'. ErbB receptor signaling by neuregulin-2. Exp Cell Res. 2008. ↩︎
'Carter MR, et al'. Neuregulin signaling in peripheral neuropathy. J Neurosci. 2002. ↩︎
'Kanamaru Y, et al'. Neuregulin-2 promotes oligodendrocyte differentiation. J Neurosci Res. 2011. ↩︎ ↩︎
'Brun A, et al'. Neuregulin-2 regulates synaptic plasticity. Neuroscience. 2010. ↩︎
'Abe Y, et al'. Neuregulin-2 regulates GABAergic signaling. Eur J Neurosci. 2012. ↩︎
'Stefansson H, et al'. Neuregulin 1 and schizophrenia. Am J Med Genet B. 2009. ↩︎
'Meier S, et al'. Neuregulin signaling in psychotic disorders. Schizophr Bull. 2013. ↩︎
'Chaudhury AR, et al'. Neuregulin and Alzheimer's disease. J Alzheimers Dis. 2019. ↩︎
'Yuan Y, et al'. Neuregulin-2 in Parkinson's disease models. Exp Neurol. 2018. ↩︎
'Syed MM, et al'. Neuregulin in central nervous system myelination. Neurochem Res. 2012. ↩︎
'Kao FC, et al'. Neuregulin-2 variants in autism spectrum disorder. J Neurodev Disord. 2018. ↩︎